## MOH: Molina Healthcare Inc - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.8% in mid entry zone (4.0-10.0%), top 6% cross-sectional ranking. Short-term MRS_5 (0.2%) confirms momentum alignment. Outperforming sector by 7.2%. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($150.14)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Investors to Connect**
- Source: KGET.com | 20251216T160922 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) who bought securities prior to February 5, 2025. The investigation will determine if Molina and its officers engaged in corporate wrongdoing. The firm encourages affected investors to connect with them for more information, noting there is no cost to them as they operate on a contingency fee basis.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Investors to Connect**
- Source: Fox 59 | 20251216T160919 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (NYSE:MOH) securities. The investigation focuses on whether Molina and its officers/directors engaged in corporate wrongdoing. Investors who purchased Molina securities before February 5, 2025, are encouraged to contact the firm to assist with the investigation.

**3. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Stockholders to Connect**
- Source: SiouxlandProud | 20251215T140837 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) for alleged corporate wrongdoing. The firm encourages stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them to assist in the investigation. The investigation seeks to determine if Molina and its officers/directors engaged in illegal activities.

**4. Molina Healthcare (MOH): Buy, Sell, or Hold Post Q3 Earnings?**
- Source: Finviz | 20251215T230300 | Neutral | Relevance: 96%
- Molina Healthcare (MOH) has seen a significant stock drop of 42.1% in the last six months, prompting questions about its future. Despite recent softer quarterly results, the company exhibits strong long-term revenue growth and benefits from economies of scale. However, weak customer growth signals potential challenges, leading to a debate on whether MOH presents a buying opportunity after its decline.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Valuation risk: PEG 2.6x with declining EPS estimates leaves no margin for error.
2. Elevated short interest (11.4%): bears positioning against stock.
3. Long-term trend broken: trading 30.0% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.62 signals overvaluation risk, limited margin of safety. Forward P/E 9.9x attractive for 18% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.8B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.62 |
| Forward P/E | 9.9 |
| Current P/E | 11.7 |
| YoY Growth | 18.1% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 11.2% to 8.8% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 0.2% confirms short-term momentum alignment. AM_20 at 6.6% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Below SMA200 (0.70x), long-term trend not supportive. MACD histogram positive (2.41), confirming momentum. RSI neutral at 58. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.82% (CS: 94) | Strong |
| RSI_14 | 57.6 | Neutral |
| MACD Histogram | 2.41 | Bullish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 0.700x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $162.26
- **Stop Loss:** $150.14 (7.5% risk)
- **Target:** $180.44 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $14,441.14
- **Portfolio %:** 14.44%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*